Figures & data
Figure 1. PubMed publications on blood eosinophils in COPD between 1991 and 2021 (accessed on July 20, 2021).
![Figure 1. PubMed publications on blood eosinophils in COPD between 1991 and 2021 (accessed on July 20, 2021).](/cms/asset/a35ab436-d64a-4028-bd5b-772590efb14d/icop_a_1985989_f0001_c.jpg)
Figure 2. Pathogenetic mechanisms including the role of eosinophils in airways inflammation in COPD.
TSLP: Thymic stromal lymphopoietin; IL: Interleukin; ILC2: Type 2 innate lymphoid cell; ILC3: Type 3 innate lymphoid cell; TNFa: Tumor Necrosis Factor a; Tc1: Cytotoxic T cell; Th: T helper cell.
![Figure 2. Pathogenetic mechanisms including the role of eosinophils in airways inflammation in COPD.TSLP: Thymic stromal lymphopoietin; IL: Interleukin; ILC2: Type 2 innate lymphoid cell; ILC3: Type 3 innate lymphoid cell; TNFa: Tumor Necrosis Factor a; Tc1: Cytotoxic T cell; Th: T helper cell.](/cms/asset/74b9f6dc-2ce1-4513-b1eb-67320805be00/icop_a_1985989_f0002_c.jpg)
Figure 3. Factors affecting the decision for the use of ICS in stable COPD, focusing on the role of blood eosinophil counts. Dashed line represents schematically blood eosinophils as a continuous variable.
AECOPD: acute exacerbations of COPD; BEC: blood eosinophil counts; FEV1: forced expiratory volume in 1 second.
![Figure 3. Factors affecting the decision for the use of ICS in stable COPD, focusing on the role of blood eosinophil counts. Dashed line represents schematically blood eosinophils as a continuous variable.AECOPD: acute exacerbations of COPD; BEC: blood eosinophil counts; FEV1: forced expiratory volume in 1 second.](/cms/asset/45b5bb97-fdf4-4075-8e26-8de71878a45e/icop_a_1985989_f0003_c.jpg)